Rifaximin significantly improves bloating in IBS-D
6 days ago - By Healio
In a composite of three trials, rifaximin provided a durable and significant improvement in bloating in patients with diarrhea-predominant irritable bowel syndrome as compared with placebo, according to results presented at UEG Week.
“A significantly greater percentage of patients receiving rifaximin were durable bloating responders compared to placebo using again the greater than or equal to one-point or the greater than or equal to two-point responder definition,” Brian E. Lacy, MD, PhD, from the Mayo Clinic in Jacksonville, Florida, said during his presentation.
Read more ...
Search by Tags
The headlines of Master Doctor
Three Types of Tests to Identify COVID-19
Tests to determine whether someone has COVID-19 or has previously been infected can be identified through three different tests. They are a molecular test, antigen test, and...
COVID-19 in Spain: Coronavirus Cases Top 1 Million
Spain has recorded more than one million COVID-19 cases. Spain became the first western European country to pass the landmark figure.
COVER-UP! ABC/CBS/NBC bury Hunter Biden scandals
The Big Three networks are doing everything they can to avoid investigating the latest Hunter Biden bombshells. Since the morning of October 14 when the New York Post published...
Benefits of Exercising One Arm Revealed
Training one arm was found to improve strength and decrease muscle loss in the other arm, without even moving it.
Physicians Among COVID Long-Haulers
Months after he first developed COVID-19 symptoms in March, Paul Garner, MD, of Liverpool School of Tropical Medicine in England, still feels the effects of the...
FDA approves Gilead's remdesivir as a treatment for coronavirus patients
On Thursday, the US Food and Drug Administration announced it had given full approved the antiviral drug remdesivir as a treatment for patients infected with the novel coronavirus.
Can ID Clinics Be Medical Home for Opioid Abusers?
Infectious disease clinics see many patients whose illnesses developed as a result of injection drug use. Now a program in Kentucky is expanding ID clinics' role for these...
Who's At Risk For 'Long COVID?'
About 5% of those with COVID-19 will have symptoms for eight weeks or more, according to the preprint analysis of data, CNN reported Wednesday.
FIT Could Accurately Rule Out CRC in Symptomatic Patients
Fecal immunochemical testing could be used to rule out colorectal cancer in patients with suspected symptoms and fast-track those needing urgent care, a British double-blind...
Some Adults Have Shown Symptoms Of Multisystem Inflammatory Syndrome - What...
By now, most of us have heard of MIS-C, the multisystem inflammatory syndrome that affects children who either have an active COVID-19 infection or had a COVID-19 infection a...